<DOC>
	<DOCNO>NCT00005850</DOCNO>
	<brief_summary>This trial design test efficacy fluoxetine improve patient 's quality life chemotherapy . An innovative application selective serotonin reuptake inhibitor may modulate effect fatigue , anxiety depression worsen quality life .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Fluoxetine Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary Objectives : 1 . To preliminarily test efficacy fluoxetine improve quality life patient advance non-small cell lung cancer receive chemotherapy decrease anxiety , depression fatigue . 2 . To test feasibility conduct multi-center clinical trial fluoxetine administer oncologist concurrently chemotherapy patient non-small cell lung cancer . Secondary Objectives : 1 . To describe tumor response rate associate administration gemcitabine/cisplatin patient advance non-small cell lung cancer . 2 . To describe overall survival failure-free survival associate administration gemcitabine/cisplatin . 3 . To describe toxicity associate administration gemcitabine/cisplatin .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>Eligibility Criteria : 1 . Histologic Documentation : All patient must histologically cytologically document , nonsmall cell carcinoma lung ( adenocarcinoma , large cell , squamous , mixture type ) . 2 . Extent Disease : Stage IIIB/IV cancer international staging system Stage IIIIA otherwise eligible patient recurrent progressive NSCLC surgery radiotherapy . Patients Stage IIIB malignant pleural effusion , supraclavicular node involvement , contralateral hilar node eligible ( IIIB patient eligible CALGB protocol combine chemotherapy chest irradiation eligible . Patients know CNS metastasis eligible . 3 . Measurable NonMeasurable Disease Measurable Disease : Lesions accurately measure least one dimension ( long diameter record ) ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan . Nonmeasurable Disease : Only nonmeasurable disease patient illdefined mass associate postobstructive change diffuse parenchymal malignant disease eligible . All lesion , include small lesion ( long diameter &lt; 20 mm conventional technique &lt; 10 mm spiral CT scan ) truly nonmeasurable lesion , eligible . Lesions consider nonmeasurable include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Abdominal mass confirm followed imaging technique Cystic lesion 4 . Prior Treatment : No prior chemotherapy . ≥ 2 week since radiation therapy . No antidepressant treatment ( eg , selective serotonin reuptake inhibitor , tricyclic , novel antidepressant , St. John 's Wort monoamine oxidase inhibitor ) currently within last month . 5 . If patient require pain medication , pain must manage noncodeine preparation , include limited : acetaminophen , morphine base preparation ( short long act ) , hydromorphone , fentanyl , levorphanol methadone . 6 . CTC Performance Status 01 . 7 . Nonpregnant nonnursing significant risk fetus/infant . 8 . Required Initial Laboratory Data : Granulocytes ≥ 1,500/µl Platelet count ≥ 100,000/µl Serum creatinine ≤ 1.5 mg/dl Calculated CrCl ≥ 60 ml/min Bilirubin ≤ 2.0 x Upper Limit Normal ( ULN ) Serum glutamic oxaloacetic transaminase ( SGOT ) ≤ 2.0 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>fatigue</keyword>
	<keyword>anxiety disorder</keyword>
	<keyword>depression</keyword>
</DOC>